Skip to content

A clinical study on the efficacy and safety of MRA combined with SGLT-2i in patients with T2DM and CKD for delaying the progression of kidney disease

A clinical study on the efficacy and safety of MRA combined with SGLT-2i in patients with T2DM and CKD for delaying the progression of kidney disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300069024
Enrollment
Unknown
Registered
2023-03-04
Start date
2023-03-04
Completion date
Unknown
Last updated
2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus with chronic kidney disease

Interventions

Control group:None

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: The age must be > 18 years at the time of signing the informed consent form. Moreover: 1) Meet the American Diabetes Association's diagnostic criteria for type 2 diabetes 2) Screening period eGFR >=25 mL/min/1.73 m2 3) Screening period random urine albumin/creatinine ratio (UACR) >= 30mg/g or urinary albumin excretion rate (UAER) >=30mg/24h 4) K+ level <= 5.0 mmol/L during screening, sex and contraception/barrier requirements 5) Regular use of RASI for more than four weeks, unless such drugs are contraindicated or not tolerated 6) Regular use of SGLT2 inhibitors for more than four weeks

Exclusion criteria

Exclusion criteria: 1) Type 1 diabetes and other types of diabetes 2) Renal replacement therapy (dialysis, kidney transplantation status) 3) Acute kidney injury requiring dialysis within 6 months prior to the screening visit 4) Combination of cytochrome P450 isoenzyme 3A4 (CYP3A4) potent inhibitor or inducer and/or CYP3A4 medium-potency inhibitor erythromycin (discontinued at least 7 days prior to randomization), in pregnancy or lactation, or planning pregnancy during the study 5) Combined with systemic wasting diseases (malignant tumors, etc.) 6) CV event within 3 months before screening visit or percutaneous coronary intervention treatment within 1 month before screening visit 7) Known allergy to investigational drugs (including active ingredients or excipients), Addison's disease, and hepatic insufficiency up to Child-Pugh class C

Design outcomes

Primary

MeasureTime frame
Urine albumin creatinine ratio;Glomerular filtration rate;

Secondary

MeasureTime frame
Metabolic indicators;Body composition;Muscle strength;Adverse drug reactions;

Countries

china

Contacts

Public Contactliufang

West China Hospital, Sichuan University

liufangfh@163.com+86 18980601214

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026